ArticleBMC complementary medicine and therapies2025
Insights into the antiviral mechanisms of β-caryophyllene: inhibiting viral spread and its synergy with acyclovir.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHSV-1 infections are pervasive in the general population of the world, and the gradual development of resistance to conventional antiviral therapies underlines the need to investigate alternative therapies. The present paper investigates the antiviral potential of a bicyclic sesquiterpene, β-caryophyllene (BCP), present in essential oils against Human alpha herpesvirus 1 (HSV-1).
methodsThe antiviral action of β-caryophyllene (BCP) was investigated using plaque reduction assays, molecular docking, molecular dynamics simulations, and surface plasmon resonance (SPR) analysis to explore its interactions with key surface glycoproteins of HSV-1 that are essential for viral entry and fusion: Glycoprotein B (gB), Glycoprotein C (gC), and Glycoprotein D (gD).
resultsBCP exhibited excellent antiviral activity, particularly during the pre-treatment phase, with a high selectivity index (SI) value of 35.86. Molecular docking analysis demonstrated that BCP binds strongly to glycoprotein B (gB) of HSV-1, with a binding energy of - 7.07 kcal/mol. These computational predictions were further validated by surface plasmon resonance (SPR) experiments, which confirmed a strong and specific interaction between BCP and gB, with a calculated equilibrium dissociation constant (KD) of (4.26 ± 0.02) × 10⁻⁶ M, supporting its proposed mechanism of action. DISCUSSION: Therefore, it was inferred that BCP interferes with viral entry and replication. Further confirmation through molecular dynamics simulation revealed less fluctuation in the Domain II region of gB, which might impede its fusion function. The SPR assay indeed confirmed that the BCP binds strongly to gB with a fast association and a slow dissociation rate, suggesting stability in this interaction.
conclusionThese findings suggest that BCP is a promising complementary therapy for HSV-1 infection, with the potential to reduce the emergence of drug resistance. However, further preclinical and clinical studies are warranted to fully validate its therapeutic efficacy and safety before patient application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.